Abstracts tagged "osteoporosis"

Abstract Number: 2501 • ACR Convergence 2025
Microvascular dysfunction contributes to hand bone deterioration in SSc patients
Rosanna Campitiello¹, Sabrina Paolino², Andrea Casabella³, Giulia Davoli², Elisa Caratto⁴, Emanuele Gotelli¹, Elvis Hysa⁵, Carmen Pizzorni², Vanessa Smith⁶, Alberto Sulli² and Maurizio Cutolo⁷, ¹University of Genoa, Genoa, Liguria, Italy, ²University of Genoa, Genova, Italy, ³IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁴Univeristy of Genoa, Alessandria, Italy, ⁵University of Genoa, Genoa, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷University of Genova, Genova, Italy
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by endothelial dysfunction, self-reactive immune response and progressive systemic fibrosis1. It is well established that…
Abstract Number: 1727 • ACR Convergence 2025
Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States
Hsu-Chih Chien, Min Kim, Michele McDermott, Mary Oates, Xiaodong Li and Lara Yoon, Amgen Inc, Thousand Oaks, CA
Background/Purpose: Current guidelines recommend treating women with postmenopausal osteoporosis (PMO) based on fracture risk. Anabolic therapy (AT), the RANKL inhibitor denosumab (Dmab), and intravenous zoledronic…
Abstract Number: 0348 • ACR Convergence 2025
Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
Karla Miller¹, Amani Jridi² and Tina Basak³, ¹University of Utah School of Medicine, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah Department of Radiology, Salt Lake City, UT
Background/Purpose: Rheumatoid arthritis (RA) patients are at higher risk of having generalized osteoporosis of the axial and appendicular skeleton assessed by dual-energy x-ray absorptiometry (DXA)…
Abstract Number: 2244 • ACR Convergence 2025
Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
Kei Hirose¹, Keigo Hayashi², Natsuki Kubota², Yuya Terajima², Kazuya Matsumoto², Takato Nakadoi², Shoichi Nawachi², Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama², Haruki Watanabe², Mariko Narazaki², Yoshinori Matsumoto² and Jun Wada², ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a well-established risk factor for fractures, due to both systemic inflammation and treatment-related effects on bone metabolism. This study aimed…
Abstract Number: 1373 • ACR Convergence 2025
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Osteoporosis is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF)…
Abstract Number: 0347 • ACR Convergence 2025
Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Kabyar Cho¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Coeliac disease (CD) is an autoimmune disease, which has been widely reported to be associated with reduced bone mineral density (BMD), leading to an…
Abstract Number: 2113 • ACR Convergence 2025
Mortality rate in patients with hip fracture: is it recommendable to establish fracture units?
Esther Monleon Acosta¹, Alicia Pérez González², José Andrés Rodríguez Fernández², Pedro José Manuel Hernández², María del Rosario Oliva Ruiz², José María Andreu Ubero², Paloma Valentina Castillo Dayer², Gloria Albaladejo Paredes³, Carlos Fernández Díaz⁴, Angela Egea Fuentes², Montserrat Fernández Salamanca² and Vicente Cogolludo Campillo⁵, ¹Hospital Santa Lucia, Cartagena, Spain, ²Hospital General Universitario Santa Lucia, Cartagena, Spain, ³Hospital General Universitario Santa Lucía, CARTAGENA, Spain, ⁴H.U. Santa Lucia, Murcia, Spain, ⁵Hospital General Universitario Santa Lucia, Santa Lucia, Cartage, Spain
Background/Purpose: Hip fracture is the second most common osteoporotic fracture and the one with the highest socio-economic cost. It is associated with high morbidity and…
Abstract Number: 1313 • ACR Convergence 2025
Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
Jonathan Barnes¹, Hamzah Amin² and marwan Bukhari³, ¹Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Steroids are used in a proportion of patients with rheumatoid arthritis (RA). Steroids are known to cause a decrease in bone mineral density (BMD),…
Abstract Number: 0346 • ACR Convergence 2025
Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
José Rodríguez gago¹, Carolina Tornero², Lina León³, María Luisa González-Casaus³, Luisa Fernanda Giraldo³, Gloria del Peso³, Diego Garrido³, Teresa López³, Mónica Coronado³, María Auxiliadora Bajo⁴, Sara García³, María Gema Serrano³, Marta Ossorio³, Alejandro Balsa³ and Pilar Aguado³, ¹Hospital Universitario La Paz, MADRID, ²Hospital La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Hospital Universitario de la Princesa - ISS Princesa, Madrid, Spain
Background/Purpose: Chronic kidney disease (CKD) is linked to increased vascular comorbidity and fracture risk. This study aims to assess bone status in CKD patients versus…
Abstract Number: 2123 • ACR Convergence 2025
Sclerostin in Aging Bone and Muscle: A Comparative Study of Osteoporosis, Sarcopenia, and Osteosarcopenia
Mohamed Tharwat Hegazy¹, Fatma Fayed¹, Shirihan Mahgoub¹, Yasmin El Ebrashy² and Maha Hossam Al-Din Ibrahim¹, ¹Faculty of Medicine, Cairo University, Cairo, Egypt, ²National institute of Diabetes and Endocrinology, Cairo, Egypt
Background/Purpose: Osteoporosis, sarcopenia, and frailty are the 3 determinants of aging. A novel syndrome of combined osteosarcopenia has negative health outcomes among geriatric populations. In…
Abstract Number: 1112 • ACR Convergence 2025
Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Manush Sondhi¹, Namrata Singh², Julie Carkin¹ and Grant Hughes³, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³University of Washington, Lynnwood, WA
Background/Purpose: The cardiovascular risks associated with osteoporosis medications remain incompletely understood. Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular…
Abstract Number: 0345 • ACR Convergence 2025
Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Hashem Cheema¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe bay NHS foundation trust, Manchester, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Low socioeconomic status is associated with.an increase in osteoporosis and fracture risk respectively. A multitude of factors have been proposed including income, educational attainment…
Abstract Number: 2122 • ACR Convergence 2025
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
Maryia Nikitsina¹, Cristina Valero², Miren Uriarte Ecenarro³, Ana M Ortiz³, María Ahijón Lana³, Irene Llorente³, Marina Dueñas-Ochoa⁴, Juan C Saez⁵, EVA GLORIA TOMERO MURIEL⁶, Esther Vicente-Rabaneda⁶, Isidoro Gonzalez-Alvaro⁷, Rosario Garcia Vicuña⁶ and Santos Castañeda⁸, ¹University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Hospital Universitario La Princesa, Madrid, Spain, ⁴Hospital La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Romosozumab (RSZ) is a dual osteoanabolic agent that stimulates bone formation and reduces bone resorption, emerging as a promising option for treating osteoporosis (OP)…
Abstract Number: 1054 • ACR Convergence 2025
Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Ye Liu¹, Hongke Wu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Polypharmacy is a major concern in osteoporosis (OP) management, especially in older adults. Romosozumab (romo), approved in April 2019, is a parenteral OP medicine…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].